Mereo BioPharma
MREO
60 hedge funds and large institutions have $99.6M invested in Mereo BioPharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 15 closing their positions.
8,000% more call options, than puts
Call options by funds: $81K | Put options by funds: $1K
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
1.52% more ownership
Funds ownership: 13.67% → 15.19% (+1.5%)
17% less funds holding
Funds holding: 72 → 60 (-12)
32% less capital invested
Capital invested by funds: $146M → $99.6M (-$46.1M)
80% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$13.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.14M |
| 3 |
CC
Clearline Capital
New York
|
+$796K |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$633K |
| 5 |
BlackRock
New York
|
+$360K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.02M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.6M |
| 3 |
SCP
Sender Company & Partners
New York
|
-$534K |
| 4 |
CAM
Connacht Asset Management
New York
|
-$341K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$157K |
MREO Hedge Fund Activity: Q1 2022 in Review
60 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2022, worth a combined $99.6M — down 32% from $146M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of MREO and 3 opened new positions — a net loss of 12 holders — while 12 trimmed existing stakes and 22 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $13.1M. The largest seller was Vivo Capital, cutting an estimated $4.02M.
- 60 institutional investors held Mereo BioPharma (MREO) as of Q1 2022, down from 72 in Q4 2021.
- Funds reported $99.6M of Mereo BioPharma stock for Q1 2022, down 32% quarter-over-quarter.
- 3 funds opened new Mereo BioPharma positions in Q1 2022 and 15 closed out, a net change of -12 holders.
- The largest Mereo BioPharma buyer in Q1 2022 was OrbiMed, an estimated $13.1M added.
- The largest Mereo BioPharma seller in Q1 2022 was Vivo Capital, an estimated $4.02M sold.
Based on aggregated 13F filings for Q1 2022.